Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tonabacase (LSVT-1701) in Complicated S. aureus Bacteremia (ERASE)
NCT05329168Phase 2Withdrawn
- Sponsor
- Lysovant Sciences
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tonabacase in Staphylococcus aureus bacteremia (SAB) and infective endocarditis (IE), sponsored by Lysovant Sciences. Primary endpoints: Incidence of treatment-emergent adverse events at Day 90, Incidence of Grade 3 or Grade 4 toxicity at Day 42 and 1 more. Planned start May 2022; status: withdrawn.
02
Drugs
tonabacase
03
Conditions
Staphylococcus aureus bacteremia (SAB)infective endocarditis (IE)
Beyond the preview
Go deeper on NCT05329168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329168.